CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 8-K: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -0.98.

EBIT: As of FY2025 Q2, the actual value is USD -1.317 M.

Financial Metrics by Segment

Cash and Cash Equivalents

• As of June 30, 2025: $4.3 million
• As of December 31, 2024: $3.2 million

Net Cash Used in Operating Activities

• For the three months ended June 30, 2025: $1.1 million

Research and Development Expenses

• For the three months ended June 30, 2025: $0.1 million
• For the three months ended June 30, 2024: $2.0 million

General and Administrative Expenses

• For the three months ended June 30, 2025: $1.2 million
• For the three months ended June 30, 2024: $1.6 million

Net Loss

• For the three months ended June 30, 2025: $1.3 million
• For the three months ended June 30, 2024: $3.3 million

Operating Loss

• For the three months ended June 30, 2025: - $1.3 million
• For the three months ended June 30, 2024: - $3.6 million

Total Other Income (Expense), Net

• For the three months ended June 30, 2025: $1 thousand
• For the three months ended June 30, 2024: - $25 thousand

Dividend on Convertible Exchangeable Preferred Shares

• For the three months ended June 30, 2025: - $20 thousand

Outlook / Guidance

Cyclacel Pharmaceuticals, Inc. anticipates that its current cash resources will fund planned expenditures into the fourth quarter of 2025. The company continues to develop its pipeline of novel drug candidates addressing oncology and hematology indications. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on innovative cancer medicines.